KRAS and colorectal carcinoma: Another option to test would be the combination of proteasome inhibitors with DNA-damaging drugs as indicated by the findings that the pre-treatment with gemcitabine, irinotecan and doxorubicin sensitized mut-KRAS CRC cells to a subsequent exposure to low concentrations of proteasome inhibitors [111].